ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1988

Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases

Ryo Rokutanda1, Chisun Min2, Yuko Kataoka1, Tokutaro Tsuda1, Shunya Kaneshita1, Ken-ichi Yamaguchi3, Koji Takasugi4, Masei Suda1, Akira Takeda3, Yukio Matsui1,3, Mitsumasa Kishimoto1 and Masato Okada1, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 3Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 4Imuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ,

Session Information

Date: Monday, November 9, 2015

Title: Vasculitis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease characterized by aching and morning stiffness of body, which is seen almost exclusively in adults over the age of 50. Glucocorticoid has been mainstay of the treatment, and methotrexate is generally recommended in patients resistant to initial steroid therapy. However, since several studies have shown greater toxicity of methotrexate in elderly patients, searching for less toxic immunosuppressive agent is warranted. Mizoribine (MZR) is an immunosuppressive agent which inhibits lymphocyte proliferation via inhibitory effect on the synthesis of inosine monophosphate dehydrogenase. While its efficacy and well tolerability for rheumatoid arthritis, systemic lupus erythematosus, autoimmune nephritis and suppression of rejection in renal transplantation is well established, few studies have examined the use of MZR for PMR.

Methods: We extracted all the patients who were given MZR for treatment of PMR during the period of July 2009 to June 2014. Retrospective medical charts review were performed to check the patients’ background, duration and drug survival rate of MZR use, and reasons for discontinuation. Serum inflammatory markers and dose of corticosteroids at the time of last follow-up were compared those at the time of MZR initiation.

Results: Forty-seven PMR patients (16 male and 31 female, mean aged 73.5±7.9 year old) were treated by MZR during the study period. Mean disease duration at the time of MZR initiation and mean duration of MZR use are 415±61 days and 423±345 days, respectively. Twelve patients had discontinued MZR, and the reasons of discontinuation are as follows: remission (4 paitents), ineffectiveness (4patients), and adverse reaction (4 patients). The dose of PSL at the time of last follow-up was significantly lower than the PSL dose at the time of MZR initiation.

Conclusion: Mizroribine shows efficacy and well-tolerability in patients with polymyalgia rheumatica.

Disclosure: R. Rokutanda, None; C. Min, None; Y. Kataoka, None; T. Tsuda, None; S. Kaneshita, None; K. I. Yamaguchi, None; K. Takasugi, None; M. Suda, None; A. Takeda, None; Y. Matsui, None; M. Kishimoto, None; M. Okada, None.

To cite this abstract in AMA style:

Rokutanda R, Min C, Kataoka Y, Tsuda T, Kaneshita S, Yamaguchi KI, Takasugi K, Suda M, Takeda A, Matsui Y, Kishimoto M, Okada M. Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-mizoribine-for-polymyalgia-rheumatica-analysis-of-47-cases/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-mizoribine-for-polymyalgia-rheumatica-analysis-of-47-cases/